Who are ExPEC9V's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Boostrix™-US formulation, Staphylococcus and Neisseria Tablets, Propionibacterium Acnes, Pertussis containing vaccine, AVA, Hib.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/expec9v.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

ExPEC9V — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ExPEC9V (ExPEC9V) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bacterial vaccine. Area: Immunology / Infectious Disease.

phase 3 Bacterial vaccine Extraintestinal pathogenic E. coli (ExPEC) antigens Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

ExPEC9V (ExPEC9V) — Janssen Research & Development, LLC. ExPEC9V is a vaccine designed to stimulate immune responses against extraintestinal pathogenic E. coli (ExPEC) strains.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ExPEC9V TARGET	ExPEC9V	Janssen Research & Development, LLC	phase 3	Bacterial vaccine	Extraintestinal pathogenic E. coli (ExPEC) antigens
Boostrix™-US formulation	Boostrix™-US formulation	GlaxoSmithKline	marketed	Inactivated bacterial vaccine
Staphylococcus and Neisseria Tablets	Staphylococcus and Neisseria Tablets	Peking University Third Hospital	marketed	bacterial vaccine
Propionibacterium Acnes	Propionibacterium Acnes	Treviso Regional Hospital	marketed	Bacterial vaccine	Propionibacterium acnes antigens
Pertussis containing vaccine	Pertussis containing vaccine	St George's, University of London	marketed	Bacterial vaccine
AVA	AVA	Emergent BioSolutions	marketed	Inactivated bacterial vaccine	Bacillus anthracis protective antigen (PA) and lethal factor
Hib	hib	Pfizer	marketed	bacterial vaccine	Haemophilus influenzae type b

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bacterial vaccine class)

Janssen Research & Development, LLC · 1 drug in this class
Sanofi · 1 drug in this class
St George's, University of London · 1 drug in this class
Treviso Regional Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ExPEC9V — Competitive Intelligence Brief. https://druglandscape.com/ci/expec9v. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing